There are currently 1881 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
NCT04796012
Recruiting
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Solid Tumor, Rhabdomyosarcoma
Register for Updates
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310
Recruiting
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
06/18/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus
Register for Updates
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT04704661
Recruiting
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Advanced Colon Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Salivary Gland Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Salivary Gland Carcinoma, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Salivary Gland Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
SPEARHEAD-3 Pediatric Study
NCT05642455
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philedephia, Philadelphia, Pennsylvania
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Osteosarcoma, Neuroblastoma (NBL)
Register for Updates
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
NCT06564974
Recruiting
The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.
Gender:
MALE
Ages:
2 years and above
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
Conditions: Duchenne Muscular Dystrophy
Register for Updates
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Autism Spectrum Disorder
Register for Updates
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/18/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Pulmonary Embolism
Register for Updates
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2025
Locations: Temple University Health Systems/ Lewis Katz School of Medicine, Philadelphia, Pennsylvania
Conditions: Lupus Erythematosus, Systemic
Register for Updates
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662
Recruiting
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates